• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Healthcare·4DX.AX
Share

4DMedical Limited Stocks

A$ 4.26Last Updated 01.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

A$ 1.69B

A$ 4.26
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, an advanced system for four-dimensional lung imaging. Beyond this core offering, its suite of products includes a software-as-a-service (SaaS) delivery model, specialized XV lung ventilation analysis software, and Permetium—a preclinical imaging system designed to quantify regional changes in pulmonary function. Additionally, the firm provides the AccuVent 200, a ventilator tailored for small animals.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 4DX.AX is 4.22 and suggests 0.706% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.10.2026 18:41

A Test of Resilience: What Nubank and Revolut Will Face in the U.S. Market

01.10.2026 18:08

A Classic Makes a Comeback: The 60/40 Portfolio Could Be Effective for the First Time Since 2021

01.10.2026 17:30

Shares of biotech company Capricor had their best day in a month. What inspired investors?

01.10.2026 16:53

From Coke to IMAX: 10 Companies Bloomberg Recommends Watching in the Fourth Quarter

01.10.2026 15:45

Morning in New York: Indices Seek Equilibrium

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026